Tigecycline use in serious nosocomial infections: a drug use evaluation

• Published in: BMC infectious diseases Vol. 10; no. 1; p. 287
• Main Authors: Bassetti, Matteo, Nicolini, Laura, Repetto, Ernestina, Righi, Elda, Del Bono, Valerio, Viscoli, Claudio
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 29.09.2010; BioMed Central; BMC
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents - adverse effects; Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Bacteria; Bacteria - drug effects; Bacterial Infections - drug therapy; Bacterial Infections - pathology; Care and treatment; Case Report; Case studies; Cross infection; Cross Infection - drug therapy; Cross Infection - pathology; Female; Hospitals, University; Humans; Infections; Male; Middle Aged; Minocycline - adverse effects; Minocycline - analogs & derivatives; Minocycline - pharmacology; Minocycline - therapeutic use; Mortality; Nosocomial infections; Patient outcomes; Prospective Studies; Time Factors; Treatment Outcome; Young Adult; Italy
• ISSN: 1471-2334; 1471-2334
• DOI: 10.1186/1471-2334-10-287

Tigecycline is a novel antibiotic with activity against multidrug resistant bacteria. The aim of this study was to assess the efficacy of tigecycline use in serious hospital-acquired infections (HAI) CASE PRESENTATION: Prospective observational study of tigecycline use was conducted in a 1500 beds university hospital. From January 1, 2007 and January 31, 2010, 207 pts were treated with tigecycline for the following indications: intra-abdominal, pneumonia, bloodstream and complicated skin and soft tissue infections and febrile neutropenia. The therapy was targeted in 130/207 (63%) and empirical in 77/207 (37%) patients. All bacteria treated were susceptible to tigecycline. Median duration of tigecycline therapy was 13 days (range, 6-28). Clinical success was obtained in 151/207 (73%) cases, with the highest success rate recorded in intra-abdominal infections [81/99 (82%)]. Microbiological success was achieved in 100/129 (78%) treated patients. Adverse clinical events were seen in 16/207 patients (7.7%): Considering the lack of data on tigecycline for critically ill patients, we think that the reported data of our clinical experience despite some limitations can be useful for clinicians.